PAPatricia Andrade-Gordon

Patricia Andrade-Gordon

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Patricia Andrade-Gordon has a total of 53 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Evidence for a proinflammatory role of proteinase‐activated receptor‐2 during cutaneous inflammation in vivo

    by M. Steinhoff, S. Seeliger, C. Derian, R. Nawroth, C. Sunderkötter, D. Metze, D. Vestweber, P. Andrade‐Gordon, T. A. Luger


  • Thrombin Regulation of Cell Function through Protease-Activated Receptors: Implications for Therapeutic Intervention

    by C. K. Derian, B. P. Damiano, M. R. D'ANdrea, P. Andrade-Gordon

    The serine protease thrombin is well recognized as being pivotal to the maintenance of hemostasis under both normal and pathological conditions. Its cellular actions are mediated through a unique...


  • Antiplatelet and Antithrombotic Activity of RWJ-53308, A Novel Orally Active Glycoprotein IIb/IIIa Antagonist

    by Bruce P Damiano, John A Mitchell, Edward Giardino, Thomas Corcoran, Barbara J Haertlein, Lawrence de Garavilla, Jack A Kauffman, William J Hoekstra, Bruce E Maryanoff, Patricia Andrade-Gordon


  • Administration of a Potent Antagonist of Protease-Activated Receptor-1 (PAR-1) Attenuates Vascular Restenosis Following Balloon Angioplasty in Rats

    by Patricia Andrade-Gordon, Claudia K. Derian, Bruce E. Maryanoff, Han-Cheng Zhang, Michael F. Addo, Wai-Man Cheung, Bruce P. Damiano, Michael R. D'ANdrea, Andrew L. Darrow, Lawrence de Garavilla, et al.


    • 1 March 2001
      • Vol. 76  (2) , 97-106

    Application of triple immunohistochemistry to characterize amyloid plaque-associated inflammation in brains with Alzheimer's disease.

    by M R Dandrea, P A Reiser, N A Gumula, B M Hertzog, P Andrade-Gordon

    Inflammation, characterized by the presence of activated microglia and reactive astrocytes (gliosis), has been described in Alzheimer's disease (AD). We used our routine single immunohistochemical (IHC) labeling protocol to label amyloid plaques, an AD neuropathological hallmark, activated microglia, and reactive astrocytes in serial sections of AD hippocampus and entorhinal cortex of brain. Although most amyloid plaques were associated with inflammation throughout the serial sections, the extent of microglial and astrocytic activation varied among the amyloid plaques. We also observed a population of amyloid plaques that did not appear to coincide with immunolabeled microglia and astrocytes in serial sections, leading us to speculate that some amyloid plaques are not associated with inflammation. Because serial sectioning limited our ability to confirm these findings, we developed a triple IHC protocol to investigate the association of activated microglia and reactive astrocytes simultaneously with amyloid plaques in sections of AD brain entorhinal cortex and hippocampus. Unlike the potential errors of extrapolating descriptive information from routine IHC or histochemical staining methods on sectioned tissues, triple IHC allowed direct characterization of three differently colored antigens in situ. The success of the protocol depended on selection of distinguishable color schemes and resolution of other critical technical elements including the compatibility of the reagents and the sensitivity and sequence of the detection systems. The results of the triple IHC protocol clarified the spatial relation of microglia and astrocytes with amyloid plaques and provoked novel interpretations about the roles of inflammation in AD brain tissues. We categorized three distinct populations of amyloid plaques related to of inflammation: 1) Abeta42 immunoreactive (a marker of amyloid plaques) amyloid plaques without activated microglia or reactive astrocytes, 2) Abeta42-positive amyloid plaques with HLA-DR (a marker of microglia)-positive microglia and no astrocytes, 3) Abeta42-positive amyloid plaques among HLA-DR and GFAP (a marker of astrocytes) immunoreactive astrocytes. Most amyloid plaques had varying degrees of activated microglia and reactive astrocytes. Some of the amyloid plaques were not associated with inflammation while others were associated only with activated microglia. These findings suggest that amyloid plaques without associated inflammation may represent recently formed plaques and that the presence of amyloid plaques in AD brains may activate microglia prior to gliosis. Furthermore, the shape of the amyloid plaques may be altered subsequently from its typical spherical to an aspherical shape by the inflammatory cells.


  • Open Access

    Design, synthesis, and biological characterization of a peptide-mimetic antagonist for a tethered-ligand receptor

    by Patricia Andrade-Gordon, Bruce E. Maryanoff, Claudia K. Derian, Han-Cheng Zhang, Michael F. Addo, Andrew L. Darrow, Annette J. Eckardt, William J. Hoekstra, David F. McComsey, Donna Oksenberg, et al.

    Protease-activated receptors (PARs) represent a unique family of seven-transmembrane G protein-coupled receptors, which are enzymatically cleaved to expose a truncated extracellular N terminus that acts as a tethered activating ligand. PAR-1 is cleaved and activated by the serine protease α-thrombin, is expressed in various tissues (e.g., platelets and vascular cells), and is involved in cellular responses associated with hemostasis, proliferation, and tissue injury. We have discovered a series of potent peptide-mimetic antagonists of PAR-1, exemplified by RWJ-56110. Spatial relationships between important functional groups of the PAR-1 agonist peptide epitope SFLLRN were employed to design and synthesize candidate ligands with appropriate groups attached to a rigid molecular scaffold. Prototype RWJ-53052 was identified and optimized via solid-phase parallel synthesis of chemical libraries. RWJ-56110 emerged as a potent, selective PAR-1 antagonist, devoid of PAR-1 agonist and thrombin inhibitory activity. It binds to PAR-1, interferes with PAR-1 calcium mobilization and cellular function (platelet aggregation; cell proliferation), and has no effect on PAR-2, PAR-3, or PAR-4. By flow cytometry, RWJ-56110 was confirmed as a direct inhibitor of PAR-1 activation and internalization, without affecting N-terminal cleavage. At high concentrations of α-thrombin, RWJ-56110 fully blocked activation responses in human vascular cells, albeitnotin human platelets; whereas, at high concentrations of SFLLRN-NH2, RWJ-56110 blocked activation responses inbothcell types. Thus, thrombin activates human platelets independently of PAR-1, i.e., through PAR-4, which we confirmed by PCR analysis. Selective PAR-1 antagonists, such as RWJ-56110, should serve as useful tools to study PARs and may have therapeutic potential for treating thrombosis and restenosis.


    • 15 November 1998
      • Vol. 92  (10) , 3694-700

    Protease-activated receptor 1 (PAR-1) is required and rate-limiting for thrombin-enhanced experimental pulmonary metastasis.

    by M L Nierodzik, K Chen, K Takeshita, J J Li, Y Q Huang, X S Feng, M R D'Andrea, P Andrade-Gordon, S Karpatkin

    Thrombin-treated tumor cells induce a metastatic phenotype in experimental pulmonary murine metastasis. Thrombin binds to a unique protease-activated receptor (PAR-1) that requires N-terminal proteolytic cleavage for activation by its tethered end. A 14-mer thrombin receptor activation peptide (TRAP) of the tethered end induces the same cellular changes as thrombin. Four murine tumor cells (Lewis lung, CT26 colon CA, B16F10 melanoma, and CCL163 fibroblasts) contain PAR-1, as detected by reverse transcriptase-polymerase chain reaction (RT-PCR). B16F10 cells did not contain the two other thrombin receptors, PAR-3 and glycoprotein Ib. TRAP-treated B16F10 tumor cells enhance pulmonary metastasis 41- to 48-fold (n = 17). Thrombin-treated B16F10 cells transfected with full-length murine PAR-1 sense cDNA (S6, S7, S14, and S22) enhanced their adhesion to fibronectin 1.5- to 2.4-fold (n = 5, P <.04), whereas thrombin-treated wild-type cells do not. S6 (adhesion index, 1.5-fold) and S14 (index, 2.4-fold) when examined by RT-PCR and Northern analysis showed minimal expression of PAR-1 for S6 over wild-type and considerable expression for S14. Immunohistochemistry showed greater expression of PAR-1 for S14 compared with wild-type or empty-plasmid transfected cells. In vivo experiments with the thrombin-treated S14 transfectant showed a fivefold to sixfold increase in metastases compared with empty-plasmid transfected thrombin-treated naive cells or S6 cells (n = 20, P =.0001 to .02). Antisense had no effect on thrombin-stimulated tumor mass. Thus, PAR-1 ligation and expression enhances and regulates tumor metastasis.


    • 1 July 1997
      • Vol. 8  (7) , 743-9

    Differential regulation of human keratinocyte growth and differentiation by a novel family of protease-activated receptors.

    by C K Derian, A J Eckardt, P Andrade-Gordon

    Thrombin receptor (ThrR) and protease-activated receptor-2 (PAR-2) are members of a unique G protein-coupled receptor family, which are characterized by the unveiling of a tethered peptide ligand upon proteolysis of their NH2 terminus. We have previously shown that cultured human basal keratinocytes express both receptors (R.J. Santulli et al., Proc. Natl. Acad. Sci. USA, 92: 9151-9155, 1995); however, their functional role in epidermal physiology has yet to be described. In the present study, we determined the effects of receptor activation on keratinocyte cell growth and differentiation using thrombin (selective for ThrR), SLIGRL (selective for PAR-2), and SFLLRN (stimulates ThrR and PAR-2), as agonists. ThrR stimulation enhanced cell growth in a dose-dependent manner in the absence of growth factors (epidermal growth factor and bovine pituitary extract). In contrast, under the same conditions, activation of PAR-2 led to the inhibition of cell growth. This inhibitory activity by PAR-2 activation was also observed in the presence of growth factors. Activation of both receptors diminished protein expression of the differentiation marker transglutaminase type 1 induced by either calcium or IFN-gamma. Calcium-induced involucrin expression was also decreased. These results indicate that PAR-2 and ThrR differentially modulate keratinocyte function and may provide an important regulatory function in the epidermis by altering the functional state of keratinocytes.